Monday, 20 May 2019

You are here

Timing of Shoulder Injections Impacts Surgical Infection Risk

A study of patients undergoing arthroscopic rotator cuff repair shows that corticosteroid injections in the month prior to surgery are associated with a significantly increased risk of surgical site infection.

A large claims database review examined patients undergoing arthroscopic rotator cuff repair and compared those undergoing arthroscopic rotator cuff repair within 1 year of injection (n=12,060), and those undergoing arthroscopic rotator cuff repair without prior injection (n = 48,763).  The primary outcome was surgical site infection within 6 months of the procedure. 

While there was no overall difference in the incidence of surgical site infection in patients receiving a shoulder injection (0.7%) and those without injection (0.8%), the investigators did find a significantly higher rate of infection in patients receiving an injection within 1 month prior (1.3% vs 0.8%; R, 1.7 [95% CI, 1.0 to 2.9]; p = 0.04).

Risk factors for infections included being male (OR, 1.7), obesity (OR 1.4), diabetes (OR 1.3), smoking (OR 1.7) and and preoperative corticosteroid injections within 1 month of the surgical procedure (OR, 2.1). 

Corticosteroid injections should be avoided if surgical arthroscopic rotator cuff repair is soon contemplated. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Generic Price Fixing Alleged by State Prosecutors

The NY Times and 60 Minutes have reported that Connecticut, along with 43 other states, filed a mega-lawsuit accusing the generic drug makers of a massive, systematic conspiracy to bilk consumers out of billions of dollars. (Citation source: https://buff.ly/2vSmv03)

Drug Pricing Regulations in US and Canada

Reuters reports on regulatory efforts by Canada and the US to curb the rising cost of drugs, especially expensive new medicines. 

In Canada, a little-known government agency is increasing its oversight of expensive drugs sold in Canada. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs introduced in the last several years by drug makers.

Nonadherence is Costly for Patients in Pain

A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs. 

Naproxen has no Effect on Alzheimer's

A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).

The INTREPAD trial was a 2-year double-masked prevention trial, that enrolled 195 AD who were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS).

Dietary Supplements Fail to Reduce Mortality Risks

An NIH funded prospective study has shown that the use of daily dietary supplements was not associated with a subsequent lowering of mortality risk.